Fresh Tracks Therapeutics Inc. (NASDAQ:FRTX) shares traded 5.78% higher at $1.83 on Wall Street last session.
In accordance with the data, 1 analysts cover Fresh Tracks Therapeutics Inc. (NASDAQ:FRTX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $12.00 and a low of $12.00, we find $12.00. Given the previous closing price of $1.73, this indicates a potential upside of 593.64 percent. FRTX stock price is now -4.74% away from the 50-day moving average and -36.70% away from the 200-day moving average. The market capitalization of the company currently stands at $5.65M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $12.00 as their price target over the next twelve months.
A total of 1.15% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FRTX stock. A new stake in Fresh Tracks Therapeutics Inc. shares was purchased by SILVERARC CAPITAL MANAGEMENT, LLC during the first quarter worth $18,000. In total, there are 19 active investors with 11.90% ownership of the company’s stock.
Fresh Tracks Therapeutics Inc. (NASDAQ: FRTX) opened at $1.7745 on Tuesday. During the past 12 months, Fresh Tracks Therapeutics Inc. has had a low of $1.30 and a high of $18.94. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.40, and a quick ratio of 4.40. The fifty day moving average price for FRTX is $1.9212 and a two-hundred day moving average price translates $2.8907 for the stock.
The latest earnings results from Fresh Tracks Therapeutics Inc. (NASDAQ: FRTX) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$2.07, missing analysts’ expectations of -$1.89 by -0.18. This compares to -$7.15 EPS in the same period last year. The company reported revenue of $0.49 million for the quarter, compared to $0.13 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 268.18 percent. For the current quarter, analysts expect FRTX to generate $2.5M in revenue.
Fresh Tracks Therapeutics Inc.(FRTX) Company Profile
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Leave a Reply